Health-related quality of life after sustained virological response to treatment for hepatitis C
Hiroshima Journal of Medical Sciences Volume 73 Issue 1-2
Page 1-7
published_at 2024-06
アクセス数 : 52 件
ダウンロード数 : 14 件
今月のアクセス数 : 1 件
今月のダウンロード数 : 0 件
この文献の参照には次のURLをご利用ください : https://ir.lib.hiroshima-u.ac.jp/00055341
File |
HiroshimaJMedSci_73_1.pdf
1.11 MB
種類 :
fulltext
|
Title ( eng ) |
Health-related quality of life after sustained virological response to treatment for hepatitis C
|
Creator |
MASUMOTO Fumi
Bunthen E
SEIKE Masataka
AKUTA Norio
KUMADA Takashi
KARINO Yoshiyasu
|
Source Title |
Hiroshima Journal of Medical Sciences
|
Volume | 73 |
Issue | 1-2 |
Start Page | 1 |
End Page | 7 |
Number of Pages | 7 |
Journal Identifire |
[PISSN] 0018-2052
[EISSN] 2433-7668
[NCID] AA00664312
|
Abstract |
This study aimed to show the changes in health-related quality of life (HRQoL) after a sustained virological response (SVR) to hepatitis C treatment. A retrospective study was conducted among 1,546 patients with SVR to interferon-based (IFN-based) or direct-acting antiviral (DAA) anti hepatitis C virus treatments from January 1990 to March 2017 in five hospitals. The survey was conducted between November 2017 and October 2018. A questionnaire including the Japanese version of the EQ-5D-3L before and after SVR by IFN-based or DAA treatment was used to assess changes in HRQoL retrospectively. Of the 1,546 patients who achieved SVR, 580 achieved SVR with IFN-based treatment (SVR-IFN) and 966 achieved SVR with DAA treatment (SVR-DAA). Comparison of HRQoL before and after treatment revealed a significant increase in SVR-IFN (0.9078 vs. 0.9278, p = 0.0406). For SVR-IFN, patients in their 60s and 70s showed a significant increase in HRQoL after treatment. In contrast, changes in HRQoL in SVR-DAA were not statistically significant (0.9018 vs. 0.9063, p = 0.3908). For SVR-DAA, HRQoL significantly improved for patients in their 50s and 60s. The results of this study showed a trend toward improvement or unchanged HRQoL in patients who achieved SVR, despite advanced age. The results of this study can serve as a basis for follow-up after SVR and cost-effectiveness analyses.
|
Keywords |
Hepatitis C
Interferons
Japan
Quality of Life
|
Language |
eng
|
Resource Type | departmental bulletin paper |
Publisher |
Hiroshima University Medical Press
|
Date of Issued | 2024-06 |
Rights |
Copyright (c) 2024 Hiroshima University Medical Press
|
Publish Type | Version of Record |
Access Rights | open access |
助成機関名 |
日本医療研究開発機構
Japan Agency for Medical Research and Development (AMED)
|
助成機関識別子 |
[Crossref Funder] https://doi.org/10.13039/100009619
|
研究課題名 | |
研究課題番号 |
17fk0210104h0001
|